14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
SANA vs VSTM: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
SANA Captures Overall Composite Edge (44.3 HOLD vs 56.9 HOLD), While VSTM Leads 4–1 on Growth & Valuation Pillars
SANA Overall Winner
6-Pillar Tally: SANA 1 – 4 VSTM (1 Tie)
Matrix Metrics: SANA 3 – 5 VSTM
As of Nov 16, 2026, Sana Biotechnology, Inc. (SANA) captures the overall head-to-head institutional edge over Verastem, Inc. (VSTM) on higher Unified Composite conviction (44.3/100 HOLD vs. 56.9/100 HOLD) after splitting the core matrix 3–5 (led by Profitability & Quality), while VSTM wins 4–1 across the 6-pillar growth and valuation breakdown. SANA trades at $1.88 (N/M Forward P/E, 0.0% operating margin) versus VSTM at $7.70 (N/M Forward P/E, -193.7% operating margin).
Composite vs. Pillar Nuance: While VSTM currently prints a higher short-term Unified Composite Score (56.9/100 HOLD vs. SANA 44.3/100 HOLD), SANA captures the overall institutional head-to-head verdict (3–5 matrix metrics and 1–4 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -193.7% operating margin) and revenue trajectory (+0.0% vs. +113.6% YoY).
Technical & Structure Timing Caution: SANA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 30.6); meanwhile VSTM trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 38.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on SANA vs VSTM. Trailing 12-month operating profitability (SANA 0.0% vs VSTM -193.7%) and valuation multiples (SANA N/M vs VSTM N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $1.0B market capitalization and -193.7% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ SANA vs VSTM Key Questions & Quantitative Answers
As of Nov 16, 2026, Sana Biotechnology, Inc. (SANA) captures the overall head-to-head institutional edge over Verastem, Inc. (VSTM) on higher Unified Composite conviction (44.3/100 HOLD vs. 56.9/100 HOLD) after splitting the core matrix 3–5 (led by Profitability & Quality), while VSTM wins 4–1 across the 6-pillar growth and valuation breakdown. SANA trades at $1.88 (N/M Forward P/E, 0.0% operating margin) versus VSTM at $7.70 (N/M Forward P/E, -193.7% operating margin). Composite vs. Pillar Nuance: While VSTM currently prints a higher short-term Unified Composite Score (56.9/100 HOLD vs. SANA 44.3/100 HOLD), SANA captures the overall institutional head-to-head verdict (3–5 matrix metrics and 1–4 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -193.7% operating margin) and revenue trajectory (+0.0% vs. +113.6% YoY). Technical & Structure Timing Caution: SANA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 30.6); meanwhile VSTM trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 38.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
VSTM leads the Growth & Scale pillar: SANA posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with VSTM at +113.6% YoY revenue growth and +0.0% YoY earnings growth on $100M TTM revenue (87.2% gross margin, -193.7% operating margin). On trailing 12-month operating scale, SANA generates N/A in USD-normalized revenue versus $100M for VSTM. In operating R&D and SG&A reinvestment, SANA deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for VSTM.
VSTM screens cheaper on headline valuation multiples. SANA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas VSTM trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 9.8x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against SANA (-79.5% ROE) versus VSTM (-471.2% ROE) capital efficiency.
In options market volatility and institutional positioning, SANA carries 105.5% implied volatility (4th %ile, Compressed (<25th %ile)), a 0.61x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.82β · 78% Vol realized risk). By comparison, VSTM carries 88.4% implied volatility (8th %ile, Compressed (<25th %ile)), a 0.01x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (1.11β · 71% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.